Indoco Remedies Q1 FY27: net profit up 282% to ₹64.99 crore, revenue up 7%
Indoco Remedies (NSE: INDOCO) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹468 crore (+6.8% year on year), net profit of ₹64.99 crore (+281.6%), earnings per share of ₹7.09. The company is valued at about ₹2,091 crore.
What happened
Indoco Remedies (NSE: INDOCO) informed the stock exchanges on 27 October 2026 at 12:47 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹468 crore (+6.8% year on year), net profit of ₹64.99 crore (+281.6%), earnings per share of ₹7.09.
Company snapshot
Indoco Remedies is a small-cap company, with a market value of about ₹2,091 crore.
The stock last traded at ₹226.5, against a 52-week range of ₹162.2–₹288 (21.4% below the high).
Before this filing the shares had moved −9.8% over the month and −8.7% over three months. Average daily turnover over the last 20 sessions was about ₹33.42 crore.
Promoters held 58.86% at the end of Q1 FY27. Foreign institutions owned 1.27% and domestic institutions 17.68%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 438 | -35.8 | -3.94 |
| Q2 FY26 | 485 | -7.9 | -1 |
| Q3 FY26 | 445 | -29.8 | -3.2 |
| Q4 FY26 | 476 | -21.6 | -2.57 |
| Q1 FY27 | 468 | 65 | 7.09 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Market-wide, 9,766 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 27 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Indoco Remedies Limited Estimates – NSE:INDOCO
- Indoco Remedies Shares Slid Even Though It Turned A Profit
- Indoco Remedies Q2 Results: Company swings to ₹19.5 crore profit, revenue rises 7.4%
- Indoco Remedies Share Price Quietly Does Something Most Mid-Cap Pharma Stocks Won’t
- Pharma sector stocks today, October 15: Panacea Biotec falls 1.75%, Wockhardt down 1.12%, Indoco Remedies down 1%
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.